Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.3%

2 terminated out of 24 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

21%

5 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed with results

Key Signals

3 with results82% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (10)
P 1 (2)
P 2 (1)
P 3 (4)
P 4 (1)

Trial Status

Completed9
Recruiting6
Not Yet Recruiting5
Terminated2
Active Not Recruiting1
Enrolling By Invitation1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT04652700Phase 3TerminatedPrimary

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT07071623Phase 3Recruiting

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT06056544Not ApplicableEnrolling By Invitation

Client-Centered Care Coordination for Black Men Who Have Sex With Men

NCT06580587Phase 1Completed

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

NCT07044297Phase 3Recruiting

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07462611Not ApplicableNot Yet RecruitingPrimary

HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study

NCT07047716Phase 3RecruitingPrimary

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07218211Phase 4Recruiting

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

NCT07379658Not Yet RecruitingPrimary

Long-Acting Injectable HIV PrEP PROs

NCT06045507Phase 2Completed

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

NCT06799702Not ApplicableNot Yet RecruitingPrimary

Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)

NCT06566417Completed

Social Media as a Risk Tool for HIV Prevention Needs

NCT06205368Not ApplicableActive Not Recruiting

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men

NCT07173816Not ApplicableNot Yet RecruitingPrimary

Optimizing PrEP Uptake for African American Women in the South by Empowering Women to Make Informed HIV Prevention and Sexual Health Choices

NCT07146139Not ApplicableTerminatedPrimary

MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women

NCT05984030Not ApplicableCompletedPrimary

Supporting Tailored And Responsive PrEP in Rural North Carolina

NCT07089966Not ApplicableNot Yet Recruiting

HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics

NCT06783192Phase 1Completed

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT05545449CompletedPrimary

Adapting an Adolescent Friendly PrEP Program for Uasin Gishu County-Kenya

NCT04754139Not ApplicableCompletedPrimary

A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population

Scroll to load more

Research Network

Activity Timeline